Sotagliflozin

Drug Profile

Sotagliflozin

Alternative Names: [14C]-LX4211; LP-802034; LX-4211; SAR 439954

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Lexicon Pharmaceuticals; Sanofi
  • Class Alcohols; Antihyperglycaemics; Glycosides; Pyrans; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Sodium-glucose transporter 1 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 21 Dec 2016 Top-line efficacy and adverse events data from a phase III inTandem2 trial in Type-1 diabetes mellitus released by Lexicon Pharmaceuticals
  • 05 Dec 2016 Topline efficacy and safety data from phase II trial in Type-1 diabetes mellitus released by Lexicon Pharmaceuticals
  • 01 Nov 2016 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in Hungary (PO) (EudraCT2016-001800-49)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top